Table 3. Summary of phase II clinical trials of a taxane plus estramustine for patients with hormone-refractory prostate cancer.
| Author | Taxane regimen | N | Median age (yrs) | >50% PSA decline | Response in measurable disease |
|---|---|---|---|---|---|
| Hudes et al (1997) | Paclitaxel 120 mg m−2 q 3 wk | 34 | 69 | 53% | 44% (4/9) |
| Smith et al (1999) | Paclitaxel 135 mg m−2 q 3 wk | 37 | 64 | 65% | 45% (10/22) |
| Petrylak et al (2000) | Docetaxel 70 mg m−2 q 3 wk | 37 | 69 | 68% | 55% (4/7) |
| Savarese et al CALGB (2001) | Docetaxel 70 mg m−2 q 3 wk+hydrocortisone | 46 | 73 | 68% | 50% (12/24) |
| Sinibaldi et al (2002) | Docetaxel 70 mg m−2 q 3 wk | 40 | 68 | 45% | 20% (4/20) |
| Copur et al (2001) | Docetaxel 30 mg m−2 wk | 30 | 74 | 76% | 58% |
CALGB=Cancer and Leukaemia Group B; hr=hour; N=number of patients; PSA=prostate-specific antigen; wk=week; yrs=years; q=every; d=day.